Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID‑19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04409509
Recruitment Status : Recruiting
First Posted : June 1, 2020
Last Update Posted : July 8, 2020
Sponsor:
Information provided by (Responsible Party):
CSL Behring

Brief Summary:
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)

Condition or disease Intervention/treatment Phase
Coronavirus Disease 2019 (COVID‑19) Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 124 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)
Actual Study Start Date : July 1, 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CSL312
Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously

Placebo Comparator: Placebo
CSL312 diluent administered intravenously
Drug: Placebo
CSL312 diluent administered intravenously




Primary Outcome Measures :
  1. The incidence of tracheal intubation or death prior to tracheal intubation [ Time Frame: From randomization to Day 28 ]

Secondary Outcome Measures :
  1. Proportion of subjects with death from all causes [ Time Frame: From randomization to Day 28 ]
  2. Proportion of subjects intubated [ Time Frame: From randomization to Day 28 ]
  3. Number and proportion of subjects with ≥ 2‑point improvement on National Institute of Allergy and Infectious Diseases (NIAID) Ordinal scale [ Time Frame: From randomization to Day 28 ]
  4. Number and proportion of subjects within each of the categories of the NIAID [ Time Frame: From randomization to Day 28 ]
  5. Proportion of subjects requiring continuous positive airway pressure (CPAP) [ Time Frame: From randomization to Day 28 ]
  6. Proportion of subjects requiring bilevel positive airway pressure (BiPAP) [ Time Frame: From randomization to Day 28 ]
  7. Proportion of subjects requiring high‑flow nasal cannula (HFNC) [ Time Frame: From randomization to Day 28 ]
  8. Proportion of subjects requiring extracorporeal membrane oxygenation (ECMO) [ Time Frame: From randomization to Day 28 ]
  9. Maximum change from baseline in Sequential Organ Failure Assessment (SOFA) score [ Time Frame: From randomization to Day 28 ]
  10. Average SOFA score over the subject's duration of the study [ Time Frame: From randomization to Day 28 ]
  11. Length of hospital stay [ Time Frame: From randomization to Day 28 ]
  12. Number and proportion of subjects experiencing Adverse Events (AEs) [ Time Frame: Up to 28 days after CSL312 or placebo administration ]
  13. Number and proportion of subjects experiencing serious adverse events (SAEs) [ Time Frame: Up to 28 days after CSL312 or placebo administration ]
  14. Number and proportion of subjects with adverse events of special interest (AESIs) [ Time Frame: Up to 28 days after CSL312 or placebo administration ]
  15. Number and proportion of subjects with CSL312 induced anti‑CSL312 antibodies [ Time Frame: Up to 28 days after CSL312 or placebo administration ]
  16. Maximum plasma concentration (Cmax) of CSL312 [ Time Frame: Up to 28 days after CSL312 administration ]
  17. Time to maximum plasma concentration (Tmax) of CSL312 [ Time Frame: Up to 28 days after CSL312 administration ]
  18. Area under the plasma concentration‑time curve (AUC) of CSL312 [ Time Frame: Up to 28 days after CSL312 administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Positive for SARS CoV 2 infection confirmed by a clinically acceptable test
  • Chest CT scan or X ray results confirming interstitial pneumonia
  • At least 1 of the following:

    • Respiratory frequency > 30 breaths per minute
    • SpO2 ≤ 93% on room air
    • Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300
    • SpO2/FiO2) ratio < 218 (if PaO2/FiO2 ratio is not available)
    • Radiographic lung infiltrates > 50%

Exclusion Criteria:

  • Currently enrolled, planning to enroll, or participated, within the last 30 days, in a clinical study requiring administration of an IMP, including expanded access or compassionate use
  • Pregnant or breastfeeding (female subjects)
  • Intubated and require mechanical ventilation (including ECMO) at the time of randomization
  • In the opinion of the investigator, the subject is expected to be intubated in the first 24 hours after IMP administration
  • Has a Do-Not-Intubate (DNI) or Do-Not-Resuscitate (DNR) order
  • In the opinion of the investigator, not expected to survive for > 48 hours after admission
  • Presence of any of the following comorbid conditions prior to randomization and prior to SARS CoV 2 infection:

    • Severe heart failure (New York Heart Association Class IV)
    • End stage renal disease (Stage ≥ 4) or need for renal replacement therapy
    • Biopsy confirmed cirrhosis, portal hypertension, or hepatic encephalopathy
    • Malignancy (Stage IV)
    • Chronic lung disease requiring the use of oxygen at home
    • Active tuberculosis disease
  • Active bleeding or a current clinically significant coagulopathy (eg, international normalized ratio [INR] > 1.5) or clinically significant risk for bleeding (eg, recent intracranial hemorrhage or bleeding peptic ulcer within the last 4 weeks)
  • History of venous thrombosis, myocardial infarction or cerebrovascular event within 3 months, or a prothrombotic disorder (eg, antithrombin III, protein C or protein S deficiency)
  • Known or suspected Grade 3 or 4 infusion-related reaction or hypersensitivity (per Common Terminology Criteria for Adverse Events [CTCAE]) to monoclonal antibody therapy, or hypersensitivity to the IMP or any excipients of the IMP
  • Currently receiving a therapy not permitted during the study.
  • Female subject of childbearing potential or fertile male subject either not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 30 days after receipt of the last dose of IMP
  • Any clinical or laboratory abnormality or other underlying conditions (eg, psychological disorders, substance abuse) that would render the subject unsuitable for participation in the study, in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04409509


Contacts
Layout table for location contacts
Contact: Trial Registration Coordinator 610-878-4000 clinicaltrials@cslbehring.com

Locations
Layout table for location information
United States, New Jersey
Inspira Health Center Vineland Recruiting
Vineland, New Jersey, United States, 08360
Sponsors and Collaborators
CSL Behring
Investigators
Layout table for investigator information
Study Director: Study Director CSL Behring
Layout table for additonal information
Responsible Party: CSL Behring
ClinicalTrials.gov Identifier: NCT04409509    
Other Study ID Numbers: CSL312_COVID-19
First Posted: June 1, 2020    Key Record Dates
Last Update Posted: July 8, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access Criteria:

Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.

An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.

The requesting party must execute an appropriate data sharing agreement before IPD will be made available.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Antibodies
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs